Research Matters 2021
CLINICAL TRIALS: MOVING RESEARCH FROM THE LAB TO THE CLINIC (CONTINUED)
The Clinical Accelerator Initiative, guided by the Translational Advisory Group (TAG), is building a network of sites to conduct small clinical trials of 10-20 patients each. These trials will dramatically inform research, enabling investigators to quickly determine if patients are responding to specific treatment approaches and why—information that will continually enhance our approach in clinical trials and clinical care.
Translational Advisory Group members represent the following institutions:
A PHASE 2 STUDY OF PLERIXAFOR AND CEMIPLIMAB IN METASTATIC PANCREATIC CANCER Lustgarten-funded researchers are also conducting a phase 2 study of Plerixafor, an immunostimulant, in combination with Cemiplimab, a PD-L1 inhibitor, to determine if this combination will activate a patient’s own tumor-killing T cells to shrink pancreatic tumors. The trial is based on research led by Lustgarten-funded Distinguished Scholar Douglas Fearon, MD.
This trial is funded by the Stephen and Nancy Grand Philanthropic Fund.
I’M VERY HOPEFUL ABOUT THE FUTURE AS WE BEGIN MOVING OUR SCIENCE INTO THE CLINIC. THIS IS THE NEXT STEP IN OUR EFFORTS TO MAKE PANCREATIC CANCER HISTORY AND IT IS ONLY POSSIBLE BECAUSE OF LUSTGARTEN FOUNDATION FUNDING.
” —David Tuveson, MD, PhD,
Chief Scientist, Lustgarten Foundation
Powered by FlippingBook